Hormonal
Aging blunts the ability for serial sarcomerogenesis (addition of new sarcomeres in series), leading to shortened fascicle length and impaired muscle mechanical function, primarily due to age-related impairments in mechanotransduction pathways like mTOR, IGF-1, and SRF signaling.
For older adults, maintaining or improving muscle function may require specific interventions that promote muscle lengthening, such as eccentric resistance training or chronic stretching. While muscle mass loss is common, the shortening of muscle fascicles (due to loss of serial sarcomeres) contributes significantly to stiffness and reduced power. Targeted training that emphasizes the lengthening phase of movements may help mitigate these age-related architectural changes, though the response may be slower or smaller than in younger individuals.
This blunted effect may be partly due to age-related impairments in the pathways regulating mechanotransduction, muscle gene expression, and protein synthesis, as some have been implicated in SSN adaptation.
Why this rating
The paper is a narrative review summarizing multiple studies; direct human evidence for SSN changes in aging is limited by reliance on ultrasound-derived fascicle length assumptions rather than direct sarcomere counting.
Source
The importance of serial sarcomere addition for muscle function and the impact of aging
Avery Hinks et al. · Journal of Applied Physiology · 2023
DOI 10.1152/japplphysiol.00205.2023
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →